Information and Resources for Investors | Alnylam

Learn more about Alnylam’s response to COVID-19 ›

Webcast – Alnylam Announces Q1 2026 Financial Earnings
LEARN MORE ›
LEARN MORE ›
CEO Yvonne Greenstreet reflects on a transformational year.

Alnylam Publishes 2025 Annual Report
Webcast: 44th annual J.P Morgan Healthcare Conference Presentation and Q&A Breakouts Session
Watch Replay ›
LEARN MORE ›
$250 million investment will add capacity and new enzymatic ligation capabilities

Alnylam Announces Expansion of U.S. Manufacturing Facility
LEARN MORE ›
What The Boston Globe Top Place to Work survey reveals about our success

11 Insights from 11 Years on the List
LEARN MORE ›
Now available to treat a new group of patients in the U.S.

FDA Grants Expanded Indication for AMVUTTRA® (vutrisiran) in the U.S.
LEARN MORE ›
In partnership with Sanofi, this is our 6th Alnylam-discovered approval in the U.S.

FDA Approves Qfitlia™ (fitusiran)
LEARN MORE ›
We’ve published our fifth annual Corporate Responsibility Report

Corporate Responsibility at Alnylam
Webcast - Alnylam’s 2025 R&D Day
Watch Replay ›

EVENTS & PRESENTATIONS

Apr 30, 2026

Alnylam Pharmaceuticals Q1 2026 Earnings Conference Call

Past Events ›

Mar 24, 2026

Alnylam TTR Investor Webinar

Past Events ›

Mar 02, 2026

46th Annual TD Cowen Healthcare Conference

Past Events ›

View all events and presentations ›

2025 Annual Report

2024 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q1 2026 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2026 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

May 04, 2026

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Apr 30, 2026

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Apr 16, 2026

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

View all press releases ›